Categories: All postsAnalysts

Descartes Systems Group has no upside, Industrial Alliance says

Descartes CEO Ed Ryan.
In a research update to clients on Tuesday, Descartes Systems Group (Descartes Systems Group stock Quote, Chart TSX:DSG, NASDAQ:DSGX) gets a price target raise from Blair Abernethy of Industrial Alliance Securities. It’s still not enough to move the needle, however, as the analyst maintains his “Hold” rating on the stock.

Not only one of Canada’s most venerable tech companies, logistics management SaaS provider Descartes Systems is also known for its ability to acquire and absorb businesses. Descartes has made dozens of acquisitions since its IPO in 1998, this year featuring cloud-based transportation management company Aljex Software Inc and airline shipment tracker Velocity Mail.

Abernethy takes Descartes’ acquisition activity into account in his estimates which now include a contribution for future acquisitions. The analyst says the company is currently exhibiting organic growth of around five per cent, driven for the most part by its faster growth businesses such as MacroPoint, acquired in 2017, along with trade content services, cross selling and higher global trade volumes.

Inorganically, Abernethy sees acquisitions playing an increasingly important role in Descartes business model and in its revenue growth during recent years.

Descartes Systems Group stock is fully valued

“On our count, the company has completed 13 acquisitions in the past three years, including the larger $107 million MacroPoint and $76 million MK Data deals. Excluding these larger deals, Descartes acquired 11 companies at an average value of ~$18 million per transaction,” says Abernethy. (All figures in US dollars.)

“Given Descartes’ financial strength and the pace of smaller acquisitions, despite currently high prices in the marketplace, we now are more comfortable including unannounced future acquisitions in our forecast. At this stage, we will not model in larger transactions ($100 million+), but only smaller tuck-ins,” he says.

Abernethy’s 2018 and 2019 estimates remain unchanged at revenue, EBITDA and Adj. EPS fully diluted in 2018 of $237.2 million, $80.4 million and $1.03 per share and in 2019 of $277.5 million, 93.9 million and $1.18 per share. For 2020, the analyst expects Descartes to produce revenue, EBITDA and Adj. EPS f.d. of $311.5 million (was $297.6 million), $107.3 million (was $100.2 million) and $1.35 per share (was $1.26 per share).

For potential catalysts, the analyst is watching for large-scale accretive acquisitions, significant retail vertical wins and improved organic revenue from new products.

Abernethy’s new price target of $33.00 (was $29.00) represents a projected 12-month return on investment of negative 2.5 per cent at the time of publication.

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

Tagged with: dsg
Jayson MacLean

Jayson is a writer, researcher and educator with a PhD in political philosophy from the University of Ottawa. His interests range from bioethics and innovations in the health sciences to governance, social justice and the history of ideas.

Recent Posts

Is Peloton Stock a Buy? (May, 2024)

Following news of a restructuring, Roth MKM analyst George Kelly has chopped his price target on Peloton (Peloton Stock Quote,… [Read More]

3 days ago

Is Ascend Wellness stock a buy?

Ahead of the company's first quarter results, Beacon analyst Russell Stanley thinks Ascend Wellness (Ascend Wellness Stock Quote, Chart, News,… [Read More]

3 days ago

Paradigm chops price target on Snipp Interactive

Following the company's fourth quarter results, Paradigm Capital analyst Daniel Rosenberg has cut his price target on Snipp Interactive (Snipp… [Read More]

3 days ago

It’s time to buy cannabis stocks, this analyst says

A major development came down the pipe this week at the U.S. Drug Enforcement Agency has reportedly decided to reschedule… [Read More]

3 days ago

Is Generac stock a buy?

Following the company's first quarter results, Roth MKM analyst Chip Moore remains neutral on Generac Holdings (Generac Holdings Stock Quote,… [Read More]

4 days ago

Bombardier is a buy, Desjardins says (May, 2024)

The stock has climbed slowly but surely since last October. But is there still money to be made on Bombardier?… [Read More]

4 days ago